IDEAYA Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
IDEAYA Biosciences, Inc. (IDYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.20% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-04
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.20%, a 2.44% increase year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.20%, a 4.55% decline year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 4.10%, a 2.38% decline year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.10%, a 12.77% decline year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.40%, a 6.38% decline from fiscal 2024.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.70%, a 2.08% decline from fiscal 2023.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.80%, a 17.07% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.10%, a 192.86% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 4.20% 10-Q · filed 2026-08-04 | 4.20% 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | 4.20% 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | 4.40% 10-K · filed 2026-02-17 | ||||
| 2025-09-30 | 4.10% 10-Q · filed 2025-11-04 | 4.40% 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 4.10% 10-Q · filed 2026-08-04 | 4.40% 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | 4.40% 10-Q · filed 2026-05-05 | ||||
| 2024-12-31 | 4.70% 10-K · filed 2026-02-17 | ||||
| 2024-09-30 | 4.20% 10-Q · filed 2025-11-04 | 4.70% 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | 4.70% 10-Q · filed 2025-08-05 | 4.70% 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | 4.30% 10-Q · filed 2025-05-06 | ||||
| 2023-12-31 | 4.80% 10-K · filed 2026-02-17 | 4.83% 10-K · filed 2024-02-20 | |||
| 2023-09-30 | 4.60% 10-Q · filed 2024-11-04 | 4.60% 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | 4.10% 10-Q · filed 2024-08-06 | 4.10% 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | 4.10% 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | 4.10% 10-K · filed 2025-02-18 | 4.05% 10-K · filed 2023-03-07 | |||
| 2022-09-30 | 3.90% 10-Q · filed 2023-11-07 | 3.90% 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 3.00% 10-Q · filed 2023-08-10 | 3.00% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 2.40% 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | 1.40% 10-K · filed 2024-02-20 | ||||
| 2021-09-30 | 1.20% 10-Q · filed 2022-11-08 | 1.20% 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-15 | 1.10% 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | 1.10% 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | 1.50% 10-K · filed 2023-03-07 | ||||
| 2020-09-30 | 0.40% 10-Q · filed 2021-11-15 | 1.50% 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | 0.50% 10-Q · filed 2021-08-10 | 1.50% 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | 1.50% 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | 2.50% 10-K · filed 2022-03-18 | ||||
| 2019-09-30 | 1.90% 10-Q · filed 2020-11-12 | 2.50% 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | 2.50% 10-Q · filed 2020-08-12 | ||||
| 2019-03-31 | 2.50% 10-Q · filed 2020-05-12 | ||||
| 2018-12-31 | 3.10% 10-K · filed 2021-03-23 | ||||
| 2018-09-30 | 2.90% 10-Q · filed 2019-11-13 | 2.90% 10-Q · filed 2019-11-13 | |||
| 2018-06-30 | 2.90% 10-Q · filed 2019-08-12 | 2.90% 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | 2.30% 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |